Feed RDY
RD

Dr. Reddy's Laboratories

RDY · NYSE

$12.41 +1.80% (+$0.22)
1M +1.47%
Market Cap ₹990.3B
P/E Ratio 29.86x
Div. Yield 0.67%
ROE 8.94%

Bulios Fair Price

$12.88

3.8% upside

Preț actual

$12.41

Subevaluat Valoare justă Supraevaluat

Potrivit Bulios Fair Price, acțiunile RDY se tranzacționează în prezent aproape de valoarea lor justă. Cum funcționează?

Bulios Fair Price este o estimare a valorii corecte a unei acțiuni din modelul de evaluare Bulios. Este un punct de plecare pentru propria analiză, nu o recomandare de investiții. Cum funcționează?

Piotroski F-Score Moderate
5/9
Valuation
27 /100
Expensive
P/E 29.86x
P/FCF 65.39x
EV/EBITDA 18.90x
Growth
86 /100
Growing
EPS growth 33.72%
Book val. growth 20.50%
Rev. growth 14.94%
Profitability
57 /100
Moderate
Gross margin 50.15%
FCF margin 4.55%
Net margin 9.96%
Quality
40 /100
Average
ROIC 5.83%
Asset turnover 0.58x
ROE 8.94%
Debt
91 /100
Low
Debt/Equity 0.19x
Net debt/EBITDA 1.09x
Current ratio 1.90x
Stability
61 /100
Moderate
Beta 0.25x
Profitable years 6
Rev. volatility 1.55%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre RDY
Online

Despre companie

Dr. Reddy's Laboratories Limited (RDY) is an Indian pharmaceutical company specializing in the manufacturing and distribution of a wide range of medicines and generic pharmaceutical products. The company focuses on developing and producing high-quality and affordable medications for patients worldwide. Dr. Reddy's Laboratories has an extensive portfolio of products, including medicines for various therapeutic areas, such as cardiovascular, gastrointestinal, oncology, neurological, and other indications. The company is one of the leading generic pharmaceutical companies and has a strong global presence. Dr. Reddy's Laboratories invests in research and development of new pharmaceutical products and continuously expands its portfolio. Its medications comply with strict quality standards and regulations, making it a trustworthy partner for healthcare institutions, physicians, and patients. Investing in shares of Dr. Reddy's Laboratories Limited (RDY) could present an intriguing opportunity for those who believe in the growing demand for affordable and high-quality generic medicines and the long-term potential of the pharmaceutical industry.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Erez Israeli

Employees

27,527

Headquarters

Hyderabad

Evenimente viitoare

23 OCT.

Earnings

Upcoming earnings report

31d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.